AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Patients and investors alike are bracing for disappointment as AstraZeneca’s newest oral breast‑cancer therapy, Etcamah, failed to hit its primary goal in a late‑stage study. The miss threatens to shave billions from the company’s projected sales, creating uncertainty for shareholders and for women hoping for a convenient first‑line option. Etcamah was promoted as a potential blockbuster that could replace intravenous regimens, so its setback may delay the arrival of an oral alternative many oncologists were anticipating.

The setback stems from the SERENA‑4 Phase III trial, which paired Etcamah with palbociclib as an upfront treatment for advanced estrogen‑receptor‑positive breast cancer. The study’s primary efficacy endpoint was not met, adding Etcamah to a growing list of oral selective estrogen receptor degraders that have missed their marks in recent pivotal studies. The trial was intended to establish Etcamah as a first‑line option, but the data fell short of the predefined criteria.

Bloomberg notes that the missed endpoint could trim billions from future revenue, while the Wall Street Journal and STAT both report the trial’s failure. Analysts now watch for the company’s next statement on whether it will initiate additional studies, pivot to other pipeline assets, or adjust its broader breast‑cancer development agenda.